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Background: Besides serum levels of PSA, there is a lack of prostate cancer specific biomarkers. It is need to develop
new biological markers associated with the tumor behavior which would be valuable to better individualize treatment.
The aim of this study was to elucidate the relationship between single nucleotide polymorphisms (SNPs) in genes
involved in DNA repair and prostate cancer progression.
Methods: A total of 494 prostate cancer patients from a Spanish multicenter study were genotyped for 10 SNPs in
XRCC1, ERCC2, ERCC1, LIG4, ATM and TP53 genes. The SNP genotyping was made in a Biotrove OpenArray® NT Cycler.
Clinical tumor stage, diagnostic PSA serum levels, and Gleason score at diagnosis were obtained for all participants.
Genotypic and allelic frequencies were determined using the web-based environment SNPator.
Results: SNPs rs11615 (ERCC1) and rs17503908 (ATM) appeared as risk factors for prostate cancer aggressiveness.
Patients wild homozygous for these SNPs (AA and TT, respectively) were at higher risk for developing cT2b – cT4
(OR = 2.21 (confidence interval (CI) 95% 1.47 – 3.31), p < 0.001) and Gleason scores ≥ 7 (OR = 2.22 (CI 95% 1.38 – 3.57),
p < 0.001), respectively. Moreover, those patients wild homozygous for both SNPs had the greatest risk of presenting
D’Amico high-risk tumors (OR = 2.57 (CI 95% 1.28 – 5.16)).
Conclusions: Genetic variants at DNA repair genes are associated with prostate cancer progression, and would be
taken into account when assessing the malignancy of prostate cancer.
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Prostate cancer (PCa) is a complex disease highly influ-
enced by hormonal and genetic factors which would con-
dition the tumor behavior. Tumor staging, tumor grading
in terms of Gleason score and diagnostic prostate specific
antigen (PSA) serum levels are clinically used to classify
patients into different prognostic risk groups which will* Correspondence: lhenriquez@dcc.ulpgc.es
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article, unless otherwise stated.condition treatment decisions. However, it is estimated
that 293 men have to be screened and 12 men have to be
treated to avoid one death related to PCa. Although recent
advances in genomic research have made possible to iden-
tify new biomarkers for PCa, results are inconclusive [1]
and it seems to be a need for new biomarkers of tumor
behavior.
DNA is constantly damaged by endogenous oxygen free
radicals and exogenous chemicals; thus, different repair
pathways are available to reverse the different types of
DNA damage [2]. Defects in these DNA repair pathwaysioMed Central. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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tions, genomic instability, and ultimately a more aggres-
sive disease [3]. DNA repair genes play a major role in
the DNA mismatch repair pathway, which includes base
excision repair (BER), nucleotide excision repair (NER),
mismatch repair (MMR) and double strand break repair
(DSBR); and are essential for maintaining the integrity of
the genome [4]. Genetic variations in genes involved in
DNA repair would confer susceptibility to the tumor, and
would be associated to disease aggressiveness through the
alteration of DNA repair pathways [5], which could induce
tumor transformation and acquisition of oncologic prop-
erties. Single nucleotide polymorphisms (SNPs) are de-
fined as inherited mutations that are present in more than
1% of the population. Given that there are millions of
SNPs in the entire human genome, a major difficulty is
to choose target SNPs that are most likely to affect
phenotypic functions and ultimately contribute to disease
development. Candidate gene studies are focused on the
selection of genes that have been previously related to a
disease, and thus come with prior knowledge about gene
function. Among dozens of genes directly involved in
DNA repair in humans [6], six of them have been previ-
ously studied in a wide series of Spanish PCa patients
based on its relevance in the mechanism of the dis-
ease [7]: X-ray repair cross-complementing protein 1
(XRCC1), excision repair cross-complementing rodent
repair deficiency, complementation group 2 (ERCC2),
excision repair cross-complementing rodent repair de-
ficiency, complementation group 1 (ERCC1), ligase IV
(LIG4), ataxia telangiectasia mutated (ATM), and tumor
protein p53 (TP53).
The ethnic origin of the studied population is a key
factor in gene-association studies. In that sense, the lit-
erature is full of genetic variances that are risk factors
for certain diseases among subjects of an ethnic origin but
are not valid among subjects from other ethnicities [8,9].
Moreover, we have previously reported that differences in
distribution of genotypes within different populations of
the same ethnicity could be an important confounding
factor in gene-association studies [7]. In that sense, since
cohorts are often multi-ethnic, the STROGAR guidelines
recommend to report whether ethnicity was controlled for
in reporting of genotype–phenotype association, and en-
courage the use of cohorts from ethnically uniform popu-
lations [10].
We hypothesize here that genetic variations in DNA
repair genes would confer different behavior to PCa cells
and would result in a distinct clinical phenotype. Thus,
the aim of the present study was to elucidate the rela-
tionship between 10 SNPs located in 6 different genes
involved in DNA repair that have been classically associ-
ated to PCa risk [3], and tumor aggressiveness in a wide
set of Spanish PCa patients.Methods
Patients
A total of 601 patients with non-metastatic localized pros-
tate cancer (PCa) from 4 different regions of Spain (15.14%
from Andalusia, 8.48% from Basque Country, 39.60% from
Canary Islands and 36.77% from Catalonia) were included
in the study [7]. We have previously shown that differ-
ences in the distribution of genotypes within different
populations of the same ethnicity are an important con-
founding factor in genetics epidemiology. In that sense,
Andalusian subjects showed the greatest differences [7].
Thus, to homogenize the sample and minimize bias, we
excluded this subset of patients from the analyses. A total
of 494 PCa were included in the present study. All patients
provided written informed consent before sample collec-
tion. The study was approved by the Research and Ethics
Committee of each institution participant in the study:
Hospital Universitario de Gran Canaria Dr. Negrín (Las
Palmas de Gran Canaria), Hospital de la Esperanza - Parc
de Salut Mar (Barcelona), Hospital Universitario Virgen
de las Nieves (Granada), Hospital Universitari de Bellvite
(L'Hospitalet de Llobregat), Onkologikoa (Guipuzcoa),
Institut Català d'Oncologia (L'Hospitalet de Llobregat),
Hospital de la Santa Creu i Sant Pau (Barcelona) and
Hospital Universitario Virgen del Rocío (Sevilla).
Clinical tumor size (cT), diagnostic PSA serum levels, and
Gleason score [11] were recruited for all PCa patients. Clin-
ical tumor size was assessed by digital rectal examination
(DRE) followed by transrectal ultrasonography (TRUS)
and magnetic resonance imaging (MRI); PSA serum levels
were assessed by chemiluminescence in an Architect
i2000 analyzer (Abbott Laboratories, IL, USA); Gleason
score was determined in the biopsy specimen by a path-
ologist. Subjects were categorized into three risk-based re-
currence groups according to D’Amico classification [12]:
low, intermediate, and high risk. After collecting demo-
graphic and clinical data, a blood sample was taken after
the signature of informed consent. All samples were sent
by courier to the Hospital Universitario de Gran Canaria,
for DNA isolation and genotype analyses as follows.
DNA isolation and quantification
DNA was obtained from blood samples at the Hospital
Universitario de Gran Canaria Dr. Negrín. DNA was iso-
lated from 300 μl of whole-blood in an iPrep™ Purification
Instrument using the iPrep™ PureLink™ gDNA Blood Kit
(Invitrogen, by Life Technologies, Carlsbad, CA), and
its integrity was determined by NanoDrop ND-1000
(NanoDrop Technologies, Wilmington, DE).
Genes and SNPs
A total of 10 SNPs in 6 different genes involved in DNA
repair were studied (Table 1): XRCC1 (involved in base
excision repair [6]), rs25487, rs25489, rs1799782; ERCC2
Table 1 Description of clinical variables
Clinical n (%)
Clinical tumor size (cT)
cT1a – cT2a 270 (54.7)
cT2b – cT2c 141 (25.8)
cT3 – cT4 66 (13.4)
NA 17 (3.4)
Initial PSA (ng/mL)
<10 306 (61.9)
10 – 19.99 103 (20.9)
>20 79 (16.0)
NA 6 (1.2)
Gleason score
<7 226 (45.7)
7 195 (39.5)
>7 71 (14.4)
NA 2 (0.4)
D’Amico group
Low 120 (24.3)
Intermediate 184 (37.2)
High 173 (35.0)
NA 17 (3.4)
Abbreviations: PSA prostate specific antigen, NA not available.
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(involved in nucleotide excision repair [6]), rs11615;
LIG4 (involved in double-strand break repair [6]), rs1805388,
rs1805386; ATM (involved in double-strand break repair
[6]), rs17503908, rs1800057; and TP53 (involved in double-
strand break repair [6]), rs1042522.
Genotyping
The SNP genotyping was performed in a Biotrove
OpenArray® NT Cycler (Applied Biosystems, Foster City,
CA) [13]. DNA samples loaded in the OpenArray (OA)
had a A260/A280 and A260/230 ratios of 1.7-1.9, and
were adjusted to 50 ng/μl. A total of 300 ng of genomic
DNA was used. A final amount of 150 ng was incorpo-
rated into the array with the autoloader, and was geno-
typed according to the manufacturer's recommendations.
A non-template control (NTC) consisting of DNase-free
double-distilled water was introduced within each assay.
When the DNA and master mix were transferred, the
loaded OA plate was filled with an immersion fluid and
sealed with glue. The multiplex TaqMan assay reactions
were carried out in a Dual Flat Block (384-well) GeneAmp
PCR System 9700 (Applied Biosystems) with the following
PCR cycle: an initial step at 93°C for 10 minutes followed
by 50 cycles of 45 seconds at 95°C, 13 seconds at 94°C
and 2:14 minutes at 53°C; followed by a final step during
2 minutes at 25°C and holding at 4°C.The fluorescence was read using the OpenArray®
SNP Genotyping Analysis software version 1.0.5. (Applied
Biosystems). The genotyping analysis was made with the
TaqMan Genotyper software version 1.0.1. (available at:
http://www.invitrogen.com) using autocalling as the call
method. The quality value of the data points was deter-
mined by a threshold above 0.95. Genotype analysis was
performed with the same batch of chips and by the same
investigator, as previously reported [7].
Statistical analysis
Genotype and allelic frequencies were determined using
the web-based environment SNPator (SNP Analysis To
Results, from the Spain's National Genotyping Centre and
the National Institute for Bioinformatics) [14]. Relative
excess of heterozygosity was determined to check com-
patibility of genotype frequencies with Hardy-Weinberg
equilibrium (HWE). Thus, p-values from the standard
exact HWE lack of fit test were calculated using SNPator.
Comparisons of genotypic and allelic frequencies were
also done in SNPator.
All additional statistical analyses were performed using
PASW Statistics 15 (IBM Corporation, Armonk, NY,
USA).
Results
The majority of PCa patients were cT1a – cT2a (54.7%),
PSA < 10 ng/mL (61.9%), and Gleason score < 7 (45.7%).
Subsequently, a total of 120 patients (24.3%) were classi-
fied as low risk tumors according to D’Amico classifica-
tion. We did not observed clinical differences among
different regions of Spain (data not shown). Distribution
of clinical variables is detailed in Table 1.
All the genotyped samples met the quality criteria stated
above. A total of 494 PCa patients were genotyped for 10
SNPs. Of the 4,940 possible determinations, 97.17% were
successfully genotyped. The genotypic and allelic frequen-
cies are shown in Table 2. Minor allele frequencies (MAF)
were similar to those reported in the literature. All SNPs
were in HWE.
Among the 10 analyzed SNPs, rs11615 (minor allele
frequency (MAF) = 0.39) and rs17503908 (MAF = 0.09),
located in ERCC1 and ATM respectively, were signifi-
cantly different distributed among PCa patients accord-
ing to the clinical variables (Additional file 1). Thus,
rs11615 was significantly associated to the clinical tumor
size (χ2 test, p = 0.002) while rs17503908 was associated
to the Gleason score (χ2 test, p = 0.005). Concerning to
rs11615, we observed that among the 259 patients diag-
nosed as cT1a – cT2a, 175 carried the G allele (67.57%).
In the other hand, among the 66 patients diagnosed as
cT3 – cT4, 31 carried the G allele (46.97%) (Additional
file 2). With respect to rs17503908, 169 of the 224 pa-
tients (75.45%) scored with Gleason <7 were genotyped
Table 2 Genotypic and allelic frequencies among Spanish prostate cancer patients
Gene/SNP Function chr n Genotypic frequencies Allelic frequencies MAF# Functional consequence#
XRCC1 BER 19q13
rs25487* 436 CC 0.42 CT 0.48 TT 0.10 C 0.66 T 0.34 0.26 Missense
rs25489 483 CC 0.88 CT 0.12 TT 0.00 C 0.94 T 0.06 0.06 Missense
rs1799782* 487 AA 0.00 AG 0.12 GG 0.88 A 0.06 G 0.94 0.13 Missense
ERCC2 NER 19q13
rs13181 482 GG 0.10 GT 0.47 TT 0.43 G 0.34 T 0.66 0.24 Missense
ERCC1 NER 19q13
rs11615 488 AA 0.39 AG 0.46 GG 0.16 A 0.61 G 0.39 0.36 Synonymous codon
LIG4 DSBR 13q23
rs1805388† 488 AA 0.04 AG 0.25 GG 0.71 A 0.17 G 0.83 0.15 Missense
rs1805386† 480 AA 0.70 AG 0.26 GG 0.04 A 0.83 G 0.17 0.10 Synonymous codon
ATM DSBR 11q22
rs17503908 486 GG 0.00 GT 0.18 TT 0.81 G 0.09 T 0.91 0.06 Intron variant
rs1800057 486 CC 0.94 CG 0.06 GG 0.00 C 0.97 G 0.03 0.02 Missense
TP53 DSBR 17p13
rs1042522 484 CC 0.59 CG 0.35 GG 0.06 C 0.76 G 0.24 0.39 Missense
Abbreviations: BER base excision repair, NER nucleotide excision repair, DSBR double-strand break repair, chr chromosome, MAF minor allele frequency.
#Information available at: http://www.ncbi.nlm.nih.gov/projects/SNP/.
*SNPs in perfect linkage disequilibrium.
†SNPs in perfect linkage disequilibrium.
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Gleason >7 were genotyped as TT (Additional file 2).
We explored the specific role of the SNPs rs11615 and
rs17503908 in relation to the associated clinical variables.
For this, we conducted the analysis according to various
genetic models: recessive, dominant, homozygote, and het-
erozygote models (Table 3). We observed that patients car-
rying the GG+AG genotypes for rs16115 were at lower
risk for develop cT2b- cT4 tumors than those AA PCa
patients (OR = 0.50, (95% Confidence Interval (CI) 0.35 –
0.73), p < 0.0001). This result was also observed in the
heterozygote model (Table 3). Similar trend was observed
for rs17503908. Those patients carrying the GG + GT
genotypes were at lower risk for develop Gleason
scores 7 – 10 than those TT PCa patients (OR = 0.48,
(95% CI 0.30 – 0.76), p = 0.002), and this trend was also
observed in the heterozygote model (Table 3). A and T areTable 3 Univariate analysis for polymorphisms rs11615 (ERCC
Recessive model Domina
GG vs. AG + AA GG + AG
Clinical variable n SNP OR (95% CI) P OR (95%
cT, 1a-2a/2b-4 270/207 rs11615 1.02 (0.62 – 1.68) 0.928 0.50 (0.3
GG vs. GT + TT GG + GT
OR (95% CI) P OR (95%
Gleason, <7/ ≥ 7 226/266 rs17503908 NA – 0.48 (0.3
Abbreviations: OR odds ratio, CI confidence interval, NA not applicable (due to the li
Statistical test: binary logistic regression (Reference category for SNP rs11615: AA. Rthe ancestral alleles for rs11615 and rs17503908, re-
spectively. According to our results, wild homozygous ge-
notypes were associated to poor prognosis factors and
these AA-rs11615 and TT-rs175803908 PCa patients were
at higher risk for develop cT2b – cT4 (OR = 2.21 (CI 95%
1.47 – 3.31), p < 0.001) and Gleason scores ≥ 7 (OR = 2.22
(CI 95% 1.38 – 3.57), p < 0.001), respectively (data not
shown).
We studied the role of rs11615 and rs17503908 in the
context of D’Amico risk groups, a classification that esti-
mate the biologic aggressiveness of prostate cancers by
grouping them into different risk categories which re-
flect the risk of cancer growth and spread. Our results
showed that those patients carrying the TT genotype for
the rs17503908 SNP had an increased risk of developing
D’Amico high-risk tumors (OR = 1.69, (CI 95% 1.01 – 2.83),
p = 0.044). This trend was not observed for rs11615 SNP1) and rs17503908 (ATM) and clinical variables
nt model Homozygote Heterozygote
vs. AA GG vs. AA AG vs. AA
CI) P OR (95% CI) P OR (95% CI) P
5 – 0.73) <0.0001 0.67 (0.39 – 1.16) 0.152 0.45 (0.30 – 0.70) <0.0001
vs. TT GG vs. TT GT vs. TT
CI) P OR (95% CI) P OR (95% CI) P
0 – 0.76) 0.002 NA – 0.45 (0.28 – 0.72) 0.001
mited sample size: only 2 subjects genotyped as GG-rs17503908).
eference category for SNP rs17503908: TT).
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AA-TT genotypes for rs16115 and rs17503908 respectively,
had the greatest risk of developing D’Amico high-risk tu-
mors (OR = 2.57 (CI 95% 1.28 – 5.16), p = 0.008) (Figure 1).
Similar result was obtained when the series was dichoto-
mized in low vs. intermediate-high D’Amico risk groups
(OR = 1.98 (CI 95% 1.02 – 3.83), data not shown). These re-
sults are in line with previous results showed above, and
suggest that these specific genotypes are associated to poor
prognosis factors (Additional file 3).
No other polymorphism showed significant associations
with clinical variables.
Discussion
DNA damage occurs very frequently and leads to gene de-
letions, amplifications, rearrangements, and translocation
resulting in the alteration of cell homeostasis and tumor
behaviour [2]. In the present study, we investigated the as-
sociation between 10 SNPs located in DNA repair genes
and the aggressiveness of prostate cancer in a wide set
of Spanish PCa patients, following a candidate-gene ap-
proach based in a previously published study [7]. We ob-
served a strong association of genotypes AA-rs11615 and
TT-rs17503908 in the development of clinical variables of
worst prognosis. These genetic variations would influence
the nucleotide excision repair and double-strand break
repair mechanisms of DNA, possible favoring genomic in-
stability and the development of more aggressive cell phe-
notypes that would cause the appearance of tumors of
poor prognosis (i.e. D’Amico high-risk tumors).
There has been an increasing interest on the role of
SNPs in the development and progression of PCa. In that
sense, SNPs in DNA repair genes have been deeply ex-
plored, especially in the prediction of radiation-induced
toxicity [15]. ERCC1 is encoded in chromosome 19q13
and it is involved in nucleotide excision repair, forming
with XPF, a free, nuclear flap structure-specific endonucle-
ase [6]. In the context of PCa, it has been reported that
polymorphisms affecting ERCC1 may predispose prostateFigure 1 Forrest plot of odds ratios (OR) with 95% confidence interva
and D’Amico high risk recurrence group. Each diamond represents the
regression, patients were dichotomized in two groups as follows: low – intepithelial cells to malignant transformation [16], but there
is a lack of information about the role of that gene in
disease aggressiveness. Genetic variants at chromosome
19q13 have been evaluated among 7,370 PCa cases, and
no association with tumor aggressiveness was observed
[1]. Although this study includes a big series, these pa-
tients came from different countries, and the ethnic origin
was not considered as a confounding factor, especially
when differences observed within populations of the same
ethnic origin suggest that race is not a sufficient factor to
ensure the homogeneity of the sample [17], as we have
also previously published [7]. In the present study, we have
observed that PCa patients carrying AA-rs11615 genotype
were at higher risk for develop bigger tumors. Allele G, in
combination with rs3212986 (also located in ERCC1), has
been associated to low ERCC1 expression, resulting in re-
duced DNA repair and better chemotherapy/radiotherapy
response [18]. By extension, A allele would be required to
maintain normal levels of ERCC1, thus conditioning tumor
malignancy and response to treatment. In that sense, G al-
lele, which is not the ancestral allele, would confer clinical
advantage in terms of tumor size.
ATM is encoded in chromosome 11q22. In response
to double-strand breaks (DSBs), ATM phosphorylates a
variety of proteins involved in DSB repair and cell-cycle
control [6]. ATM/ATR inactivation is a crucial step in
promoting androgen-induced genomic instability and
prostate carcinogenesis [19], and some missense variants
of the ATM gene have been shown to confer a moderate
increased risk of prostate cancer. Genetic variants at
ATM have been associated with radiation-induced tox-
icity [20,21], although none of the previously reported
associations were confirmed in a validated study [22]. A
similar trend has been observed in the context of tumor
aggressiveness [23]. We have observed that PCa patients
carrying TT-rs17503908 genotype were at higher risk for
develop high-grade tumors. Thus, G allele, which is not
the ancestral allele, would confer clinical advantage in
terms of Gleason score. Although this is a novel resultl (CI) for polymorphisms rs11615 (ERCC1) and rs17503908 (ATM)
OR and the horizontal line indicates the 95% CI. For the binary logistic
ermediate vs. high D’Amico groups.
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variants exist among breast cancer patients, and some of
them can contribute to the etiology and progression of
the malignancy [24].
Since it seems that wild genotypes represent a risk factor
associated with tumor malignancy, we evaluated the com-
bined role of both genotypes in relation to risk groups
established by D’Amico. We observed that patients carry-
ing both wild homozygous genotypes (AA +TT) were at
higher risk of develop D’Amico high-risk tumors. ERCC1
and ATM are encoded in different chromosomes, thus,
there is not conserved combination of SNPs. However, ge-
notypes frequencies for AA-rs11615 and TT-rs17503908
were 0.39 and 0.81, respectively; and a total of 148 PCa
patients carried both genotypes (29.9% of the total series).
Consequently, a combined analysis would give an idea
about the role of both polymorphisms as predictors of
tumor malignancy. Nonetheless, it has to be taken into ac-
count that functional consequences of rs11615 and
rs17503908 are not missense; that is, there is not amino
acid substitution in the translated protein. However, cu-
mulative evidence suggest that synonymous mutations
are also important, and there is a rapidly growing list
of synonymous mutations that lead to human diseases
[25,26]. Synonymous SNPs could affect protein function
altering RNA secondary structures, affecting RNA stabil-
ity, and subsequently reducing protein expression [27]
and possibly affecting protein folding and function [28].
Therefore, it is possible that both polymorphisms can
be important in determining the tumor characteristics
of prostate cancer.
Candidate gene association studies are often criticized
for their lack of validation. Thus, a replication study using
an independent and random cohort of PCa patients should
be considered in near future [29]. The present study has
some weakness that need to be highlighted: i) although
494 PCa patients seem sufficient to obtain statistically reli-
able results, it is possible that some results may be of sto-
chastic nature, especially for those SNPs with lower MAF;
ii) other factors associated to prostate cancer (i.e. age, fa-
miliar aggregation, toxic habits or some kind of diets) have
not been taken into account in the present study; iii) the
observations should be confirmed in an independent co-
hort. Despite the above, the present study provides a num-
ber of advantages that contribute to their credibility: i) it is
a multicenter study that provides patients from different
areas of a country, minimizing the bias of studies per-
formed in one hospital; ii) all subjects are from Spanish
origin, and it has been reduced the possible influence of
intra ethnic variations [7]; iii) all the determinations (4,940
in total) were performed with the same methodology
(OpenArray, Applied Biosystems), with the same batch of
chips and by the same investigator, thus minimizing biases
from technical origin.Conclusions
We found that genetic variants at DNA repair genes are
associated with clinical variables of poor prognosis for
prostate cancer. Prospective studies are required to val-
idate our results.
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